Skip to main content
OpenTrials
Completed

NCT Number: NCT00413751

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Walter Reed Army Medical Center

Washington D.C., District of Columbia, 20307, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion criteria

  • Patients not meeting above stated age criteria
  • Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
  • History of serious ocular, neurological, cardiovascular disease
  • History of severe systemic disease
  • History of arrhythmias or high blood pressure
  • Patients currently taking any type of ocular or systemic medications except multivitamins.
  • Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Treatment and study plan

Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Drug

Sponsors and collaborators

Lead sponsor

Walter Reed Army Medical Center

Fed

Registry information

Important dates

First posted
Dec 20, 2006
Registry last updated
Dec 20, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.